石藥集團(01093.HK)料未來三年將上市新產品50餘個
石藥集團(01093.HK)副總裁孫聚民指,疫情期間,集團一方面配合政府積極抗疫,全力生產供應鹽酸阿比多爾,另一方面通過線上學術會議、空中課堂等,創新學術推廣形式,一定程度上化解部分影響。
他指,公司通過創新增加自己的抗壓強度,保證在變化的浪潮中不斷實現價值增值。
他又指,目前在研項目300餘項,其中小分子創新藥40餘項、大分子創新藥50餘項,主要聚焦在腫瘤、自身免疫、精神神經、消化和代謝、心腦血管系統及抗感染六大治療領域,同時積極對外尋找合作及收購的機會,為未來增長提供有力支撐。未來三年,集團將上市新產品50餘個,其中預計市場空間超過10億元的產品不少於15個。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.